873651-92-4

Usage

Uses

Used in Pharmaceutical Industry:
3-AMINO-6-PYRIDINEMETHANOL is used as a chemical intermediate for the synthesis of various drugs and drug substances, contributing to the development of new pharmaceuticals.
Used in Agrochemical Production:
3-AMINO-6-PYRIDINEMETHANOL is utilized in the production of agrochemicals, playing a role in the creation of substances that help protect and enhance crop yields.
Used as a Reagent in Chemical Processes:
3-AMINO-6-PYRIDINEMETHANOL serves as a reagent in various chemical processes, facilitating reactions that are essential in the synthesis of a range of chemical products.
Used in Medicinal Chemistry:
It has potential applications in medicinal chemistry, where it can be employed in the design and synthesis of new compounds with therapeutic potential.
Used in Material and Catalyst Development:
3-AMINO-6-PYRIDINEMETHANOL is also used in the development of new materials and catalysts, highlighting its versatility in different areas of chemistry and material science.

InChI:InChI=1/C6H8N2O/c7-5-1-2-6(4-9)8-3-5/h1-3,9H,4,7H2

Upstream product

• 100-26-5 Pyridine-2,5-dicarboxylic acid 
• 131052-40-9 methyl 5-[N-(tert-butoxycarbonyl)amino]-pyridine-2-carboxylate 
• 17874-76-9 6-(methoxycarbonyl)nicotinic acid 
• 323578-38-7 tert-butyl N-[6-(hydroxymethyl)pyridin-3-yl]carbamate 
• 55338-73-3 5-amino-2-cyanopyridine 
• 67515-76-8 methyl 5-amino-2-pyridinecarboxylate 
• 24242-20-4 5-amino-pyridine-2-carboxylic acid 
• 39658-41-8 ethyl-6-amino-nicotinate 
• 119830-47-6 ethyl 3-amino-pyridine-6-carboxylate 

Downstream Products

• 1421472-13-0 phenyl 6-(hydroxymethyl)pyridin-3-ylcarbamate 

Relevant academic research and scientific papers

Compound serving as protein kinase inhibitor and application of compound

The invention discloses a compound used as a protein kinase inhibitor and application of the compound, the compound has an obvious inhibition effect on protein kinase activity, can be used as a BTK inhibitor for preparing medicines for treating BTK-mediated diseases such as malignant tumors, autoimmune diseases and the like, and has wide application prospect.

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.

Tuning activation and self-immolative properties of the bioorthogonal alkene-azide click-and-release strategy

We report on a series of 4-azidobenzyloxy-substituted self-immolative linkers which undergo [3 + 2]-cycloaddition (click reaction) with functionalized trans-cyclooctenes (TCOs) at second-order rate constants in the range of 0.017 to 4.9 M-1 s-1. The choice of 4-azidobenzyloxy-substituted linker and the TCO play a critical role in the rate of all click-and-release steps, which includes the [3 + 2]-cycloaddition and subsequent degradation pathway of the triazoline to an aniline that undergoes 1,6- or 1,8-self-immolation of the phenol. We demonstrate that reacting a 4-azido-2,3,5,6-tetrafluorobenzyloxy-linker with a highly strained TCO (d-TCO) gives, to the best of our knowledge, the fastest TCO-strained alkene-azide click reaction to date (4.9 M-1 s-1), but with one caveat; release of phenol via 1,6-self-immolation is extremely slow. A methyl substituent attached to the benzyl carbon of this analogue maintains the rapid click-reaction rate, but has the added benefit of enabling the release of the phenol within hours. In an aqueous solvent at reagent concentrations in the micromolar range a maximium release was observed after 48 hours; ≈65 and ≈78percent of phenol released depending on the TCO used. The new suite of linkers and their combination with TCOs of varying structure add to the toolbox of bioorthogonal click-and-release reactions. This journal is

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS

Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII); or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

NEW BICYCLIC DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES

The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

PYRROLCARBOXAMIDE DERIVATIVES FOR THE INHBITION OF ERK5

The invention provides compounds of formula (I) or a tautomer, stereoisomer, N-oxide, pharmaceutically acceptable salt or solvate thereof. The compounds are useful for the prophylaxis or treatment of a disease state or condition mediated by ERK5, in particular cancers.

NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY

The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

SUBSTITUTED HETEROCYCLIC AZA DERIVATIVES

The invention relates to heterocyclic aza derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Substituted Heterocyclic Aza Compounds

Heterocyclic aza compounds as vanilloid receptor ligands, pharmaceutical compositions containing these compounds and also methods of using these compounds for the treatment and/or inhibition of pain and further diseases and/or disorders.